Edition:
United States

Medicines Co (MDCO.O)

MDCO.O on Nasdaq

35.44USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$35.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,285,481
52-wk High
$55.95
52-wk Low
$30.80

Select another date:

Wed, Aug 30 2017

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

FDA approves Medicines Co's urinary tract infection drug

The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

BRIEF-Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations

* The Medicines Company reports second quarter 2017 business and financial results

BRIEF-The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE

* The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE

BRIEF-Medicines Co says commenced implementation of workforce reduction​

* Medicines Co - ‍on june 1, 2017, Medicines company commenced implementation of a workforce reduction​

BRIEF-Medicines says U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

* Medicines-U.S. District court issued order preliminarily approving proposed settlement by co, plaintiffs in case related to co's clinical trial of Cangrelor

BRIEF-The Medicines Company Q1 loss per share $1.44

* The Medicines Company reports first-quarter 2017 financial results

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

Federal appeals court rules Mylan can proceed with generic Angiomax

A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company .

Federal appeals court rules Mylan can proceed with generic Angiomax

A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company.

Select another date: